JP2019532617A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532617A5
JP2019532617A5 JP2018568709A JP2018568709A JP2019532617A5 JP 2019532617 A5 JP2019532617 A5 JP 2019532617A5 JP 2018568709 A JP2018568709 A JP 2018568709A JP 2018568709 A JP2018568709 A JP 2018568709A JP 2019532617 A5 JP2019532617 A5 JP 2019532617A5
Authority
JP
Japan
Prior art keywords
seq
antibody
pharmaceutical composition
composition according
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018568709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532617A (ja
JP7076711B2 (ja
Filing date
Publication date
Priority claimed from US15/201,423 external-priority patent/US10464999B2/en
Application filed filed Critical
Priority claimed from PCT/IB2017/053984 external-priority patent/WO2018007922A2/en
Publication of JP2019532617A publication Critical patent/JP2019532617A/ja
Publication of JP2019532617A5 publication Critical patent/JP2019532617A5/ja
Application granted granted Critical
Publication of JP7076711B2 publication Critical patent/JP7076711B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018568709A 2016-07-02 2017-06-30 抗トランスサイレチン抗体 Active JP7076711B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/201,423 2016-07-02
US15/201,423 US10464999B2 (en) 2015-01-28 2016-07-02 Anti-transthyretin antibodies
PCT/IB2017/053984 WO2018007922A2 (en) 2016-07-02 2017-06-30 Anti-transthyretin antibodies

Publications (3)

Publication Number Publication Date
JP2019532617A JP2019532617A (ja) 2019-11-14
JP2019532617A5 true JP2019532617A5 (enExample) 2020-08-13
JP7076711B2 JP7076711B2 (ja) 2022-05-30

Family

ID=59506311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018568709A Active JP7076711B2 (ja) 2016-07-02 2017-06-30 抗トランスサイレチン抗体

Country Status (3)

Country Link
EP (1) EP3478714A2 (enExample)
JP (1) JP7076711B2 (enExample)
WO (1) WO2018007922A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
MX2020003043A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Métodos para detectar transtiretina.
MX2020003041A (es) 2017-10-06 2020-10-05 Prothena Biosciences Ltd Anticuerpos anti-transtiretina.
PH12020550694A1 (en) 2017-11-29 2021-04-12 Prothena Biosciences Ltd Lyophilized formulation of a monoclonal antibody against transthyretin
JP2023525790A (ja) 2020-05-12 2023-06-19 ニューリミューン エイジー Ttrアミロイドーシスに対する併用療法
CN114106159A (zh) * 2020-08-28 2022-03-01 安源医药科技(上海)有限公司 一种SARS-CoV-2刺突蛋白抗体及其应用
WO2022094152A1 (en) * 2020-10-28 2022-05-05 Neotope Neuroscience Limited Anti-transthyretin antibodies and methods of use thereof
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
KR20250131771A (ko) 2022-11-15 2025-09-03 뉴리뮨 아게 트랜스티레틴-매개 아밀로이드증의 치료 또는 예방 방법
WO2024240562A1 (en) 2023-05-19 2024-11-28 Neurimmune Ag Novel immunotherapy for musculoskeletal disorders and conditions
WO2025238147A1 (en) 2024-05-15 2025-11-20 Neurimmune Ag Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ATE371231T1 (de) 1999-02-05 2007-09-15 Samsung Electronics Co Ltd Verfahren und vorrichtung zur wiederauffindung von texturbildern
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ, スーパーヒト化抗体
WO2003057838A2 (en) 2001-12-28 2003-07-17 Abgenix, Inc. Antibodies against the muc18 antigen
DK1567652T3 (da) 2002-11-29 2007-11-26 Boehringer Ingelheim Pharma Nye neomycin-phosphotransferasegener og fremgangsmåde til selektion af höjtproducerende rekombinante celler
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
CA2578400C (en) 2004-11-10 2014-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
WO2007124345A2 (en) 2006-04-21 2007-11-01 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
SG182160A1 (en) 2007-03-02 2012-07-30 Boehringer Ingelheim Pharma Improvement of protein production
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
US9534048B2 (en) 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
US9790269B2 (en) * 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
TWI781507B (zh) * 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718122B (zh) * 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體

Similar Documents

Publication Publication Date Title
JP2019532617A5 (enExample)
JP2019530427A5 (enExample)
JP2019530428A5 (enExample)
JP6592059B2 (ja) アルファシヌクレインを認識するヒト化抗体
JP2018510617A5 (enExample)
JP2018506277A5 (enExample)
JP2020536532A5 (enExample)
TW202126694A (zh) 標靶cd3的抗體、雙特異性抗體及其用途
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
RU2012147286A (ru) Гуманизированные антитела к фактору d и их применения
RU2007139953A (ru) Антитела к ccr5 и их применение
JP2017526370A5 (enExample)
TW201833141A (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
CN109069622A (zh) 特异性结合人cd40的拮抗性抗体和使用方法
RU2015118180A (ru) Антитела к бета-амилоиду
RU2015115956A (ru) Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
CN104968678A (zh) 靶向epo的抗体的组合物和方法
JP2018509889A5 (enExample)
RU2009136913A (ru) Биспецифические связывающие агенты с межвидовой специфичностью
EP2377555A3 (en) Antibodies against vascular endothelial growth factor receptor-1
JP6523243B2 (ja) Baff及びb7rp1に特異的なタンパク質及びその使用
RS62214B1 (sr) Dkk-1 antitela
RU2018128812A (ru) Четырехвалентные антитела к psgl-1 и их применения
WO2014140374A2 (en) Monovalent cd27 antibodies